✦ LIBER ✦

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

Book ID: 117305460
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 248 KB
Volume: 374
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(09)61567-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sustained efficacy and immunogenicity of

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

✍ N. De Carvalho; J. Teixeira; C.M. Roteli-Martins; P. Naud; P. De Borba; T. Zahaf 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 535 KB

Efficacy of the human papillomavirus (HP

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18

✍ A. Szarewski; W.A.J. Poppe; S.R. Skinner; C.M. Wheeler; J. Paavonen; P. Naud; J. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 857 KB

Sustained efficacy up to 4·5 years of a

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

✍ Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barb 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 134 KB

Sustained efficacy up to 4·5 years of a

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

✍ Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barb 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 134 KB

## Background: Effective vaccination against hpv 16 and hpv 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. our aim was to assess the long-term efficacy, immunogenicity, and safety of a bivalent hpv-16/18 l1 virus-like part

Efficacy of human papillomavirus (HPV)-1

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

✍ J Paavonen; P Naud; J Salmerón; CM Wheeler; S-N Chow; D Apter; H Kitchener; X Ca 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 303 KB

Cross-protective efficacy of HPV-16/18 A

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

✍ Cosette M Wheeler; Xavier Castellsagué; Suzanne M Garland; Anne Szarewski; Jorma 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 221 KB